Multiple myeloma-associated VTE risk prediction. A talk report from the 10th ICTHIC
During the 10th ICTHIC, prof Kristen Sanfilippo (Assistant Professor at the Washington University School of Medicine in...
Most Read
An interview with Benjamin Brenner
Benjamin Brenner Director, Hematology and Bone Marrow Transplantation Institute – Director, Division of Internal...
Summary ESMO Clinical Practice Guideline for the management of venous thromboembolism in cancer patients
Venous thromboembolism (VTE) is the second cause of death in people with cancer, after cancer itself. Cancer and VTE...
Platelet Cut-Off for Anticoagulant Therapy in Thrombocytopenic Patients with Blood Cancer and Venous Thromboembolism
Venous thromboembolism (VTE) is a recurrent risk factor in cancer patients. In particular, patients with hematologic...
CAT management in older cancer patients
During the ICTHIC webinar, “Challenges in the management of fragile CAT patients (older patient population &...
D-dimer and its role in venous thromboembolism
D-dimer is a marker of coagulation activation and thrombotic activity. The analysis of D-dimer levels is used to...
Updates in Cancer-Associated Thrombosis
Our speakers, Laurent Bertoletti and Tzu-Fei Wang, shared some recent updates on cancer-associated...
Mouse models of cancer-associated thrombosis
Cancer patients have 4-7 fold increased risk of venous thromboembolism (VTE) compared with a general population ....
Inpatient thromboprophylaxis in cancer patients: what is the evidence? A talk report from the 10th ICTHIC
During the 10th ICTHIC, Prof. Jeffrey Zwicker (Harvard Medical School, MA, USA) gave an overview of the evidence of the...
New Predictive Model for Bleeding in Anticoagulated VTE Cancer Patients – (B-CAT Score)
In patients with active cancer who develop venous thromboembolism (Ca-VTE), major bleeding emerges as the most serious...